⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28796528 | 1.00 | TSHR (0.50) | — | |
| SCHEMBL2625315 | 1.00 | — | — | |
| SCHEMBL271356 | 1.00 | — | — | |
| SCHEMBL27338395 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL1333596 | 0.97 | — | — | |
| Acetic Acid SCHEMBL27917011 | 0.87 | RNPEP (0.41) | — | |
| SCHEMBL7136126 | 0.84 | RNPEP (0.44) | — | |
| SCHEMBL20917620 | 0.83 | TSHR (0.39) | — | |
| SCHEMBL22456 | 0.82 | TSHR (0.41) | — | |
| SCHEMBL283526 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230255945-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-9986733-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9873691-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873691-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170295777-A1 | Compositions and Methods for Reducing Ice Crystal Formation | X-THERMA, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20070281939-A1 | Benzamide Inhibitors of The P2X7 Receptor | PFIZER INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1854893-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | Kaneka Corporation (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-7176202-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |